Abstract
To design a releasable PEGylated TNF-α (rPEG-TNF-α), a cathepsin B-sensitive dipeptide (Val-Cit moiety) was inserted into conventional PEG-modified TNF-α (PEG-TNF-α), facilitating its clinical use for anti-tumor therapy. Comparative pharmacokinetic and pharmacodynamic studies showed that the half-lives of both PEGylated forms of TNF-α were ∼60-fold greater than that of unmodified TNF-α. In addition, the in vitro bioactivity of rPEG-TNF-α was greater than that of PEG-TNF-α with the same degree of PEG modification. Release of TNF-α from rPEG-TNF-α in vitro was dependent on the presence of cathepsin B and was inhibited by a cathepsin B inhibitor. Despite the potent cytotoxicity of unmodified TNF-α against normal cells, its PEGylated forms at higher TNF-α concentrations showed low cytotoxic activity against these cells. In contrast, both forms of PEGylated TNF-α showed potent cytotoxic activity against the B16 and L929 cell lines, with rPEG-TNF-α being 5- and 9-fold more potent, respectively, than PEG-TNF-α. Moreover, rPEG-TNF-α was a more potent in vivo antitumor agent than PEG-TNF-α.
Article PDF
Similar content being viewed by others
References
Chapman P B, Lester T J, Casper E S, et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol, 1987, 5: 1942–1951
Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliver Rev, 2001, 46: 169–185
Blick M, Sherwin S A, Rosenblum M, et al. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res, 1987, 47: 2986–2989
Harris J M, Chess R B. Effect of PEGylation on pharmaceuticals. Nat Rev Drug Discov, 2003, 2: 214–221
Tsutsumi Y, Kihira T, Tsunoda S, et al. Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency. Br J Cancer, 1995, 71: 963–968
Tsutsumi Y, Kihira T, Yamamoto S, et al. Chemical modification of natural human tumor necrosis factor-alpha with polyethylene glycol increases its anti-tumor potency. Jpn J Cancer Res, 1994, 85: 9–12
Tsutsumi Y, Tsunoda S, Kamada H, et al. Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency. Br J Cancer, 1996, 74: 1090–1095
Grace M, Youngster S, Gitlin G, et al. Structural and biologic characterization of PEGylated recombinant IFN-alpha2b. J Interferon Cytokine Res, 2001, 21: 1103–1115
DeFrees S, Wang Z G, Xing R, et al. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology, 2006, 16: 833–843
Shaunak S, Godwin A, Choi J W, et al. Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nat Chem Biol, 2006, 2: 312–313
Filpula D, Zhao H. Releasable PEGylation of proteins with customized linkers. Adv Drug Deliv Rev, 2008, 60: 29–49
Otto H H, Schirmeister T. Cysteine proteases and their inhibitors. Chem Rev, 1997, 97: 133–172
Hashimoto Y, Kakegawa H, Narita Y, et al. Significance of cathepsin B accumulation in synovial fluid of rheumatoid arthritis. Biochem Bioph Res Commun, 2001, 283: 334–339
Barrett A J, Kembhavi A A, Brown M A, et al. L-trans-epoxysuccinyl-leucylamido (4-guanidino) butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J, 1982, 201: 189–198
Kovar M, Strohalm J, Etrych T, et al. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect. Bioconjug Chem, 2002, 13: 206–215
Studer M, Kroger L A, DeNardo S J, et al. Influence of a peptide linker on biodistribution and metabolism of antibody-conjugated benzyl-EDTA. Comparison of enzymic digestion in vitro and in vivo. Bioconjug Chem, 1992, 3: 424–429
Versluis A J, Rump E T, Rensen P C N, et al. Synthesis of a lipophilic daunoruhicin derivative and its incorporation into lipidic carriers developed for LDL receptor-mediated tumor therapy. Pharm Res, 1998, 15: 531–537
Afar D E H, Bhaskar V, Ibsen E, et al. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther, 2004, 3: 921–932
Francisco J A, Cerveny C G, Meyer D L, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood, 2003, 102: 1458–1465
Sanderson R J, Hering M A, James S F, et al. In vivo Drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res, 2005, 11: 843–852
Dai C Y, Fu Y, Li B, et al. Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha (TNF-α) against murine fibrosarcoma. Sci China Life Sci, 2011, 54: 128–138
Stocks S J, Jones A J M, Ramey C W, et al. A fluorometric assay of the degree of modification of protein primary amines with polyethylene glycol. Anal Biochem, 1986, 154: 232–234
Yamazaki S, Onishi E, Enami K, et al. Proposal of standardized methods and reference for assaying recombinant human tumor necrosis factor. Jpn J Med Sci Biol, 1986, 39: 105–118
Kamada H, Tsutsumi Y, Tsunoda S, et al. Molecular design of conjugated tumor necrosis factor-alpha: synthesis and characteristics of polyvinyl pyrrolidone modified tumor necrosis factor-alpha. Biochem Biophys Res Commun, 1999, 257: 448–453
Ishiyama M, Tominaga H, Shiga M, et al. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 1996, 19: 1518–1520
Haranaka K, Satomi N, Sakurai A. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer, 1984, 34: 263–267
Carswell E A, Old L J, Kassel R L, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA, 1975, 72: 3666–3670
Aniento F, Roche E, Cuervo A M, et al. Uptake and degradation of glyceraldehyde-3-phosphate dehydrogenase by rat liver lysosomes. J Biol Chem, 1993, 268: 10463–10470
Murata M, Miyashita S, Yokoo C, et al. Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro. FEBS Lett, 1991, 280: 307–310
Barrett A J, Kirschke H. Cathepsin B. Methods Enzymol, 1981, 80: 535–561
Vasey P A, Kaye S B, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res, 1999, 5: 83–94
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Dai, C., Fu, Y., Chen, S. et al. Preparation and evaluation of a new releasable PEGylated tumor necrosis factor-α (TNF-α) conjugate for therapeutic application. Sci. China Life Sci. 56, 51–58 (2013). https://doi.org/10.1007/s11427-012-4431-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-012-4431-7